New Onset clinical trials at UCSF
1 research study open to eligible people
New onset means the disease began very recently. UCSF is studying low dose immune suppression then either an antibody therapy or verapamil in people newly diagnosed with type 1 diabetes. This randomized multicenter trial will follow safety and early insulin function.
Showing trials for
Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
open to eligible people ages 9-20
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.
San Francisco, California and other locations
Our lead scientists for New Onset research studies include Stephen Gitelman.
Last updated: